197 related articles for article (PubMed ID: 32021151)
1. Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Reddy AT; Lakshmi SP; Banno A; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2020; 15():125-134. PubMed ID: 32021151
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist.
Milara J; Morell A; Ballester B; Sanz C; Freire J; Qian X; Alonso-Garcia M; Morcillo E; Cortijo J
Respir Res; 2015 Feb; 16(1):12. PubMed ID: 25652132
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Milara J; Lluch J; Almudever P; Freire J; Xiaozhong Q; Cortijo J
J Allergy Clin Immunol; 2014 Aug; 134(2):314-22. PubMed ID: 24636089
[TBL] [Abstract][Full Text] [Related]
6. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
7. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
[TBL] [Abstract][Full Text] [Related]
8. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
10. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
[TBL] [Abstract][Full Text] [Related]
11. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
12. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Susuki-Miyata S; Miyata M; Lee BC; Xu H; Kai H; Yan C; Li JD
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):E1800-9. PubMed ID: 25831493
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
16. Prostanoid Receptors of the EP
Joshi R; Hamed O; Yan D; Michi AN; Mostafa MM; Wiehler S; Newton R; Giembycz MA
J Pharmacol Exp Ther; 2021 Feb; 376(2):161-180. PubMed ID: 33158942
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of roflumilast.
Lahu G; Nassr N; Hünnemeyer A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.
Milara J; Armengot M; Bañuls P; Tenor H; Beume R; Artigues E; Cortijo J
Br J Pharmacol; 2012 Aug; 166(8):2243-62. PubMed ID: 22385203
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Meyers JA; Taverna J; Chaves J; Makkinje A; Lerner A
Clin Cancer Res; 2007 Aug; 13(16):4920-7. PubMed ID: 17699872
[TBL] [Abstract][Full Text] [Related]
20. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
